IMUX (38) UNCY (45) OKUR (46) ORGO (50) ⌘ Pro Terminal →

Minerva Neurosciences Inc (NERV) — RQD Stock Rating Cockpit

$2.32 +3.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.33

Minerva Neurosciences Inc (NERV) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $107.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NERV Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NERV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Minerva Neurosciences Inc (NASDAQ: NERV) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.32 (+3.57% 1D, market cap $107.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NERV ranks #586 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NERV compare to IMUX and UNCY in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NERV carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMUX (Immunic Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $106.4M) and UNCY (Unicycive Therapeutics Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $106.1M). Among the 5-stock peer group, NERV leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NERV?

▼

Per NERV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001598646), Minerva Neurosciences Inc generated $0 in revenue, -$293.4M in net income, and -$13.5M in free cash flow against $98.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.33 (+0.45%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NERV)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY NERV SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.89-19.7% Next Q

Q2 (-2Q)

Grade D$2.32-5.2% Next Q

Q3 (-1Q)

Grade D$2.20+5.5% Next Q

Current

Grade D-$2.32-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NERV Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NERV currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.44) and Max Pain ($2.44) forces dealer call-delta covering toward $9.24.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NERV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NERV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

37.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE5% OF RANGE

L: $2$2.32H: $9

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 11 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on NERV

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (45)

-35.0% ROIC with 42.0% gross margin and -12.63% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (32)

11/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like NERV

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NERV)

✓Walkthrough of NERV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NERV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -63.35%▼ SUPPORT BREAKDOWN

2026-11-02O $2.34H $2.43L $2.32C $2.32VOL 6.7K

RES: $5.38SUP: $3.21SMA50: $3.44SMA200: $4.89

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NERV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NERV Butterfly Map → + Track NERV →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NERV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NERV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NERV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NERV)

Health Care Rank #586 of 1016 ⚔️ IMUX vs NERV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NERV vs. IMUX, UNCY, OKUR, ORGO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Minerva Neurosciences Inc (NERV) ranks #586 by composite RQD confidence (38/100, grade D-) and #650 by equity capitalization ($107.0M). Within this direct 5-issuer industry benchmark cohort, NERV leads on earnings valuation at N/A trailing P/E, while ORGO leads on capital efficiency and profitability with 17.1% ROIC and — gross margin. ORGO currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with NERV at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NERV ACTIVE Minerva Neurosciences Inc	D-	38/100	—	—	-35.0%	+3.57%	$107.0M	Benchmark Subject
IMUX Immunic Inc.	D-	38/100	—	—	-35.0%	-3.66%	$106.4M	/imux-vs-nerv →
UNCY Unicycive Therapeutics Inc.	D	45/100	—	—	-35.0%	-1.84%	$106.1M	/uncy-vs-nerv →
OKUR OnKure Therapeutics Inc. (Class A)	D	46/100	—	—	-35.0%	0.00%	$106.1M	/okur-vs-nerv →
ORGO Organogenesis Holdings Inc. (Class A)	D	50/100	—	—	17.1%	-6.20%	$105.4M	/orgo-vs-nerv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001598646

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Minerva Neurosciences Inc (NERV) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$293.4M, operating cash flow of -$13.5M, and free cash flow of -$13.5M (+30.9% YoY). On the balance sheet, NERV closed FY2025 with $98.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$293.4M	-$13.5M	-$13.5M	$98.0M	—
FY2024 (FY)	2024-12-31	$0	$1.4M	-$19.6M	-$19.6M	$37.1M	—
FY2023 (FY)	2023-12-31	$0	-$30.0M	-$14.8M	-$14.8M	—	—

3. NERV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NERV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NERV compare to IMUX and UNCY in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NERV?

Where is NERV trading relative to its 50-day, 200-day, and 52-week technical levels?

NERV last traded at $2.32 (+3.57% on volume of 394,698 shares), positioning the stock -32.56% below its 50-day simple moving average ($3.44) and -52.56% below its 200-day simple moving average ($4.89). Across its 52-week range of $1.96 to $8.80, NERV sits at the 5.3% percentile with a 14-day RSI of 37.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.03 to $2.61).

NERV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell NERV stock right now?

Minerva Neurosciences Inc (NERV) currently earns a Roarable Rating of D- (Sell — SELL) with 38/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is NERV's 12-month price target and RQD AI Jury consensus?

NERV's 12-month base price target is $2.11 (range $1.65 to $9.24), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: NERV RQD Cockpit NERV 12M Forecast NERV Earnings & Move NERV Dividends & DRIP NERV Insiders & 13F NERV Whale Options NERV Profit Sankey NERV News & Why

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

NERV — Minerva Neurosciences Inc: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:43:51Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, NERV scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 9 / 20. Per the RQD rating, ROIC is -35% and FCF yield is -12.63%. For a prospective investor, this means the business is not currently generating returns on invested capital or free cash flow, so any valuation rests on expectations of future change rather than current cash output.
Whale 13F Flow: 8 / 20. The RQD rating cites institutional accumulation and options positioning as the basis for this pillar. Flow signals of this kind can indicate changing sponsorship, but the source data does not provide the underlying 13F holdings, so the pillar cannot be verified against specific filings here.
Insider Conviction: 3 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the lowest-scoring pillar, which indicates limited insider-side conviction signals in the data.
Macro Regime Fit: 8 / 20. Per the RQD rating, beta is 1.0 and the pillar reflects sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the broader market, offering no defensive cushion.
Forensic Balance Sheet: 10 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These metrics point to a balance sheet that is neither clearly distressed nor clearly strong, with weak internal scoring on the Piotroski measure.

Taken together, the investor implication is that upside depends on a shift in the company's cash-generation profile, which the current data does not show. The valuation tradeoff is that a $107.0M market capitalization with negative returns and cash flow leaves little current earnings support for the price.

Business

Minerva Neurosciences Inc (NERV) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company has a market capitalization of $0.1B. The source data does not describe its products, customers, or revenue model. Per the FY 2025 financials, reported revenue is $0.0M.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-15.1M	$-293.4M	N/A	$-13.5M	$82.3M	N/A
FY 2024	$0.0M	$-21.8M	$1.4M	N/A	$-19.6M	$21.4M	N/A
FY 2023	$0.0M	$-23.1M	$-30.0M	N/A	$-14.8M	N/A	N/A

Per the SEC financials, reported revenue is $0.0M in each period and operating income is negative across all three years. Gross, operating, and net margins are each listed as 0% in the market data. Per the market data, ROIC is -35%. Per the RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Per the SEC financials, cash rose to $82.3M at FY 2025 from $21.4M at FY 2024, while FY 2025 net income was $-293.4M against a FY 2024 figure of $1.4M.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the headlines reference the following items, all flagged YELLOW with MARKET WIRE impact:

Coverage of a Jefferies Global Healthcare Conference presentation in London, with a related note that the talk is scheduled for Nov. 16 and will be carried by a live webcast.
A Stock Titan item on schizophrenia negative symptoms, noting that no FDA-approved treatments exist for that indication and that experts will discuss a drug still in testing.
A market commentary item referencing the stock holding near $2.40 with traders watching resistance.
Seasonal returns and research/ratings pages from Yahoo! Finance Canada, Barron's, and Yahoo Finance, which the source describes only generically.

Risk watch items: the source data does not establish the outcome of any clinical testing, and the news feed does not report trial results. The Butterfly supply-chain graph reports no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Not available in source data for upstream or downstream dependencies, sector correlations, or 2nd-order bottlenecks beyond the sector and industry classification already noted.

Open Questions

What are the specific outcomes and timelines of the clinical program referenced in the news feed, and what is the status of the drug described as still in testing?
What drove the FY 2025 net loss of $-293.4M against operating income of $-15.1M, and what non-operating items account for the gap?
What are the company's reported debt obligations, given that debt is N/A in every period?
Which institutions hold the shares, and do the 13F flows referenced in the RQD rating reflect accumulation or reduction?
What is the company's cash runway given FCF of $-13.5M in FY 2025 against cash of $82.3M?

NERV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Minerva Neurosciences Inc (NERV) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NERV Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 5h ago

Minerva Neurosciences, Inc. (NERV) Seasonal Returns Chart

Yahoo! Finance Canada report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Barron's • 8h ago

Minerva Neurosciences Inc. Research & Ratings | NERV

Barron's report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 11h ago

No FDA-approved treatments exist for schizophrenia's negative symptoms. Experts will discuss a drug still in testing.

Stock Titan report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 14h ago

Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London

Yahoo Finance report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 17h ago

A live webcast will carry Minerva's Nov. 16 talk from London.

Stock Titan report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 20h ago

Minerva Neurosciences (NERV) Holds Near $2.40 as Traders Eye Resistance - Institutional Volume

https://www.siam.in/ report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 23h ago

Most Active Stocks Today: U.S. Market

TradingKey report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Minerva (NERV) Advances +9.05% as Buying Pressure Builds 2026-10-21 - Sector Sentiment

https://www.siam.in/ report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NERV Bull vs. Bear Conversation Board — What's Your Call at $2.32?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NERV 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.97 (-12.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is NERV (D- • RQD 38/100) a Buy at $2.24?

Welcome to the NERV (Minerva Neurosciences Inc) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.75 (-21.9%)

Spot @ $2.24

Pump the brakes on NERV — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NERV, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Minerva Neurosciences Inc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.69 (+20.1%)

Spot @ $2.24

NERV cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NERV, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.24 (52-wk range $1.99 - $2.49), any beat on forward guidance forces shorts and underweight funds to chase.